EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to control advanced lung cancer
Disease control Recruiting nowThis study tests whether combining two types of drugs (EGFR-TKIs and a PD-1 antibody) can help control advanced non-small cell lung cancer with specific EGFR mutations. It involves 32 adults who have not had prior treatment. The main goal is to see how long the cancer stays under…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a pulsatile drug schedule beat brain metastases in lung cancer?
Disease control Recruiting nowThis trial is testing a higher, every-other-day dose of the drug furmonertinib in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study will compare this high-dose schedule …
Matched conditions: EGFR ACTIVATING MUTATION
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC